Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient-derived xenografts and organoids model therapy response in prostate cancer
Sofia Karkampouna, Federico La Manna, Andrej Benjak, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 119

Showing 26-50 of 119 citing articles:

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research
Mohammad Waseem, Bi‐Dar Wang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1093-1093
Open Access | Times Cited: 8
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Jie Mei, Xingjian Liu, Huixiang Tian, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 8
OBSERVE: guidelines for the refinement of rodent cancer models
Stéphanie I. De Vleeschauwer, Marieke van de Ven, Anaïs Oudin, et al.
Nature Protocols (2024) Vol. 19, Iss. 9, pp. 2571-2596
Closed Access | Times Cited: 8
Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review
Benjamin Medle, Gottfrid Sjödahl, Pontus Eriksson, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2062-2062
Open Access | Times Cited: 26
OncoLoop: A Network-Based Precision Cancer Medicine Framework
Alessandro Vasciaveo, Juan Martín Arriaga, Francisca Nunes de Almeida, et al.
Cancer Discovery (2022) Vol. 13, Iss. 2, pp. 386-409
Open Access | Times Cited: 24
Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer
Sarah Koushyar, Valérie S. Méniel, Toby J. Phesse, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 309-309
Open Access | Times Cited: 23
From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 6281-6281
Open Access | Times Cited: 23
Organoid: Bridging the gap between basic research and clinical practice
Guihu Weng, Jinxin Tao, Yueze Liu, et al.
Cancer Letters (2023) Vol. 572, pp. 216353-216353
Closed Access | Times Cited: 16
Patient‐Derived Microphysiological Systems for Precision Medicine
Jihoon Ko, Jiyoung Song, Nakwon Choi, et al.
Advanced Healthcare Materials (2023) Vol. 13, Iss. 7
Open Access | Times Cited: 15
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 5
Overcoming limitations in current measures of drug response may enable AI-driven precision oncology
Katja Ovchinnikova, Jannis Born, Panagiotis Chouvardas, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 5
Modeling prostate cancer: What does it take to build an ideal tumor model?
Chun‐Wai Mai, Kok‐Yong Chin, Lian Chee Foong, et al.
Cancer Letters (2022) Vol. 543, pp. 215794-215794
Closed Access | Times Cited: 19
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Sophie Williams, Greg Wells, Samantha Conroy, et al.
Expert Reviews in Molecular Medicine (2022) Vol. 24
Open Access | Times Cited: 19
Ponatinib: An update on its drug targets, therapeutic potential and safety
Yue Gao, Yue Ding, Xin-ran Tai, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188949-188949
Closed Access | Times Cited: 12
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
Lucie Thorel, Pierre‐Marie Morice, Hippolyte Paysant, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 12
In vitro and in vivo experimental models for cancer immunotherapy study
Chunye Zhang, Yuxiang Sui, Shuai Liu, et al.
Current Research in Biotechnology (2024) Vol. 7, pp. 100210-100210
Open Access | Times Cited: 4
Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture
Jiaxin Wang, Zhilin Sui, Wei Huang, et al.
Bioactive Materials (2024) Vol. 38, pp. 384-398
Open Access | Times Cited: 4
A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine
Jessica Kalla, Janette Pfneissl, Theresia Mair, et al.
Cellular Oncology (2024)
Open Access | Times Cited: 4
Research progress and application of liver organoids for disease modeling and regenerative therapy
Yang Hu, Qiao Geng, L. Wang, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 7, pp. 859-874
Open Access | Times Cited: 4
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance
Shauna McClelland, Pamela Maxwell, Cristina Branco, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2797-2797
Open Access | Times Cited: 4
Technological advances in clinical individualized medication for cancer therapy: from genes to whole organism
Jiejing Kai, Xueling Liu, Meijia Wu, et al.
Personalized Medicine (2025), pp. 1-14
Open Access
Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model
Hongwei Lan, Jingjuan Zhu, Helei Hou, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
A novel perspective on bone tumors: advances in organoid research
Zhengliang Ma, Yibing Liu, Rui Chen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
Federico La Manna, Marta De Menna, Nikhil Patel, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 32
Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models
Rachel Ringquist, Delta Ghoshal, Ritika Jain, et al.
Advanced Drug Delivery Reviews (2021) Vol. 179, pp. 114003-114003
Open Access | Times Cited: 25

Scroll to top